Replies to post #451594 on Anavex Life Sciences Corp (AVXL)

[crescentmotor]

"The true impact of simufilam on mild Alzheimer's disease patients is unknown, making it difficult to assess the drug's effectiveness for this group".

Says Lane Simonian, who's been singing the same song for years. He is a retired history teacher with a weak resume and no relevant experience--puts out a lot of garbage on SA. At least he has gone from full SAVA basher to recommending a hold on the stock. Amazing turnabout considering his big complaint is that Simufilam does nothing for moderate patients. Duh!!! He states that the two-year data may result in a better chance of receiving FDA approval but that is "not certain". Duh!!! Of course it is not certain. That's why two Phase III trials are being run. Interesting though that he how ranks SAVA a hold after bashing the stock for years. Funny how this newly released data that he scoffs at changed his mind.

[crescentmotor]

So why doesn't SAVA stock price get hammered down by 40% ?

It' s because Lane Simonian is putting up numbers that don't make any sense because he is cherry-picking apples and oranges from multiple available data points that he does not understand in order to support his theory. Lane Simonian does not have the raw data. According to Lane, we are to believe the cognition numbers are flat for eighteen months in the treated group and then magically fall by three points in the last six months! There is no way that reflects reality. Numerous posters over in the Discord group had put many bullet holes in Simonian's article by citing SAVA released data.

[Foodman1291]

Correctamundo…